< Back to Press
4 April 2025
Eversense 365 Wins Gold at 2025 Edison Best New Product Awards
Parsippany, United States
Award recognizes the outstanding innovation of Eversense 365 as the world’s first and only one year CGM system.
Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TYO: 6523), announced today that the Eversense® 365 Continuous Glucose Monitoring (CGM) System has received the Gold Award for Personal Healthcare Monitoring in the prestigious 2025 Edison Best New Product Awards™. Established in 1987, the Edison Awards honor excellence in new product and service development, marketing, design and innovation.
Eversense 365 is developed by Senseonics (NYSE: SENS) and brought to patients by Ascensia Diabetes Care. As the only long-term CGM available, it offers people with diabetes a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits people with diabetes, endocrinologists and care teams by delivering confidence in decision-making and long-term peace of mind. The tiny implantable sensor and unique approach to CGM also allow people to overcome common frustrations and interruptions experienced with traditional short-term CGMs, so they can focus on managing their diabetes and not their device.
Eversense 365 is currently available in the U.S. only and indicated for people with diabetes 18 years and older. Senseonics has filed for CE Mark registration for Eversense 365 to be marketed in Europe.
The mission of the Edison Awards is to be a leader in globally recognizing, honoring and fostering innovation and innovators to create a positive impact in the world. Winners are chosen by a panel of judges comprised of more than 3,000 senior business executives and academics, based on excellence the three criteria of Concept, Value, and Impact. The panel includes hundreds of past Edison Award winners as well as marketing professionals, scientists, engineers and academics.
Eversense 365 was recognized with the Gold Award in the Health, Medical & Biotech category under Personal Health Monitoring. Other categories included Commercial Technology, Engineering & Robotics, and Materials Science.
Brian Hansen, President of CGM at Ascensia, said: “As a company completely focused on diabetes management technology, Ascensia works every day to simplify and improve the lives of people with diabetes. The Edison Award is further recognition that Eversense 365, as the world’s first and only one-year CGM system, is a truly differentiated solution and a significant breakthrough. Thanks to relentless innovation from Senseonics, people with diabetes now have a product that provides them with unparalleled freedom and peace of mind. We continue to focus on bringing Eversense 365 to more people across the country and look forward to expanding outside the U.S.”
END
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/.
A media kit for Eversense 365, including images, logos and further information, can be accessed at www.ascensia.com/media/eversense365-media-kit/
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: www.ascensia.com
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2022 were JPY 356.4 billion with global distribution of products and services in more than 125 countries. www.phchd.com
Media Contacts:
